S&P 500   3,382.37 (+1.46%)
DOW   27,957.08 (+0.98%)
QQQ   272.63 (+2.81%)
AAPL   451.84 (+3.28%)
MSFT   210.07 (+3.29%)
FB   261.68 (+2.17%)
GOOGL   1,509.13 (+1.93%)
AMZN   3,168.80 (+2.86%)
NVDA   457.75 (+5.47%)
CGC   17.29 (+2.01%)
BABA   255.95 (+3.03%)
TSLA   1,574.01 (+14.52%)
GE   6.62 (-1.63%)
MU   48.55 (+1.65%)
AMD   82.45 (+7.25%)
T   30.20 (+0.03%)
F   7.09 (-1.94%)
ACB   9.83 (-1.90%)
GILD   68.88 (+1.15%)
NFLX   480.10 (+2.82%)
DIS   131.77 (+0.98%)
BAC   26.71 (-0.78%)
BA   175.15 (-2.76%)
S&P 500   3,382.37 (+1.46%)
DOW   27,957.08 (+0.98%)
QQQ   272.63 (+2.81%)
AAPL   451.84 (+3.28%)
MSFT   210.07 (+3.29%)
FB   261.68 (+2.17%)
GOOGL   1,509.13 (+1.93%)
AMZN   3,168.80 (+2.86%)
NVDA   457.75 (+5.47%)
CGC   17.29 (+2.01%)
BABA   255.95 (+3.03%)
TSLA   1,574.01 (+14.52%)
GE   6.62 (-1.63%)
MU   48.55 (+1.65%)
AMD   82.45 (+7.25%)
T   30.20 (+0.03%)
F   7.09 (-1.94%)
ACB   9.83 (-1.90%)
GILD   68.88 (+1.15%)
NFLX   480.10 (+2.82%)
DIS   131.77 (+0.98%)
BAC   26.71 (-0.78%)
BA   175.15 (-2.76%)
S&P 500   3,382.37 (+1.46%)
DOW   27,957.08 (+0.98%)
QQQ   272.63 (+2.81%)
AAPL   451.84 (+3.28%)
MSFT   210.07 (+3.29%)
FB   261.68 (+2.17%)
GOOGL   1,509.13 (+1.93%)
AMZN   3,168.80 (+2.86%)
NVDA   457.75 (+5.47%)
CGC   17.29 (+2.01%)
BABA   255.95 (+3.03%)
TSLA   1,574.01 (+14.52%)
GE   6.62 (-1.63%)
MU   48.55 (+1.65%)
AMD   82.45 (+7.25%)
T   30.20 (+0.03%)
F   7.09 (-1.94%)
ACB   9.83 (-1.90%)
GILD   68.88 (+1.15%)
NFLX   480.10 (+2.82%)
DIS   131.77 (+0.98%)
BAC   26.71 (-0.78%)
BA   175.15 (-2.76%)
S&P 500   3,382.37 (+1.46%)
DOW   27,957.08 (+0.98%)
QQQ   272.63 (+2.81%)
AAPL   451.84 (+3.28%)
MSFT   210.07 (+3.29%)
FB   261.68 (+2.17%)
GOOGL   1,509.13 (+1.93%)
AMZN   3,168.80 (+2.86%)
NVDA   457.75 (+5.47%)
CGC   17.29 (+2.01%)
BABA   255.95 (+3.03%)
TSLA   1,574.01 (+14.52%)
GE   6.62 (-1.63%)
MU   48.55 (+1.65%)
AMD   82.45 (+7.25%)
T   30.20 (+0.03%)
F   7.09 (-1.94%)
ACB   9.83 (-1.90%)
GILD   68.88 (+1.15%)
NFLX   480.10 (+2.82%)
DIS   131.77 (+0.98%)
BAC   26.71 (-0.78%)
BA   175.15 (-2.76%)
Log in

NYSE:BIOBio-Rad Laboratories Stock Price, Forecast & News

$505.27
+8.93 (+1.80 %)
(As of 08/12/2020 02:44 PM ET)
Add
Compare
Today's Range
$496.34
Now: $505.27
$505.27
50-Day Range
$432.34
MA: $490.69
$535.60
52-Week Range
$309.38
Now: $505.27
$540.06
Volume3,859 shs
Average Volume177,583 shs
Market Capitalization$15.00 billion
P/E Ratio7.83
Dividend YieldN/A
Beta1.12
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Read More
Bio-Rad Laboratories logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.6Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP09057220
Phone510-724-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.31 billion
Cash Flow$7.10 per share
Book Value$247.77 per share

Profitability

Net Income$1.76 billion

Miscellaneous

Employees8,120
Market Cap$15.00 billion
Next Earnings Date10/29/2020 (Estimated)
OptionableOptionable
$505.27
+8.93 (+1.80 %)
(As of 08/12/2020 02:44 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

How has Bio-Rad Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Bio-Rad Laboratories' stock was trading at $345.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BIO stock has increased by 46.1% and is now trading at $505.27.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Bio-Rad Laboratories?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bio-Rad Laboratories
.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Bio-Rad Laboratories
.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) posted its quarterly earnings data on Thursday, July, 30th. The medical research company reported $1.61 EPS for the quarter, topping the consensus estimate of $1.22 by $0.39. The medical research company had revenue of $536.88 million for the quarter, compared to analyst estimates of $526.80 million. Bio-Rad Laboratories had a return on equity of 3.66% and a net margin of 84.89%.
View Bio-Rad Laboratories' earnings history
.

What price target have analysts set for BIO?

4 brokerages have issued 1-year target prices for Bio-Rad Laboratories' shares. Their forecasts range from $400.00 to $625.00. On average, they anticipate Bio-Rad Laboratories' share price to reach $511.25 in the next twelve months. This suggests a possible upside of 1.2% from the stock's current price.
View analysts' price targets for Bio-Rad Laboratories
.

Has Bio-Rad Laboratories been receiving favorable news coverage?

News headlines about BIO stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bio-Rad Laboratories earned a news impact score of -2.2 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about Bio-Rad Laboratories
.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a drop in short interest during the month of January. As of January 31st, there was short interest totaling 455,000 shares, a drop of 20.8% from the January 15th total of 574,500 shares. Based on an average trading volume of 203,200 shares, the days-to-cover ratio is currently 2.2 days. Currently, 2.1% of the shares of the company are sold short.
View Bio-Rad Laboratories' Short Interest
.

Who are some of Bio-Rad Laboratories' key competitors?

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), Broadcom (AVGO), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), salesforce.com (CRM) and CVS Health (CVS).

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the following people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 69)
  • Ms. Christine A. Tsingos, Exec. Officer (Age 60)
  • Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 63)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 57)
  • Ms. Annette Tumolo, Exec. VP & Pres of Life Science Group (Age 64)

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (1.05%), Fisher Asset Management LLC (0.66%), Intermede Investment Partners Ltd (0.60%), Assenagon Asset Management S.A. (0.52%), Ardevora Asset Management LLP (0.35%) and Candriam Luxembourg S.C.A. (0.35%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Christine A Tsingos, James R Stark, John Hertia, Michael Crowley, Ronald W Hutton and Timothy S Ernst.
View institutional ownership trends for Bio-Rad Laboratories
.

Which institutional investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including Fort Washington Investment Advisors Inc. OH, Intermede Investment Partners Ltd, Principal Financial Group Inc., Russell Investments Group Ltd., Tygh Capital Management Inc., Thrivent Financial for Lutherans, FDx Advisors Inc., and Mutual of America Capital Management LLC. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include James R Stark, John Hertia, Michael Crowley, Ronald W Hutton, and Timothy S Ernst.
View insider buying and selling activity for Bio-Rad Laboratories
.

Which institutional investors are buying Bio-Rad Laboratories stock?

BIO stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Ardevora Asset Management LLP, Assenagon Asset Management S.A., Assetmark Inc., Hexavest Inc., Candriam Luxembourg S.C.A., Teacher Retirement System of Texas, and Natixis Advisors L.P..
View insider buying and selling activity for Bio-Rad Laboratories
.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $505.27.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $15.00 billion and generates $2.31 billion in revenue each year. The medical research company earns $1.76 billion in net income (profit) each year or $7.06 on an earnings per share basis. Bio-Rad Laboratories employs 8,120 workers across the globe.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is www.bio-rad.com.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.